Recently, dual HER2 inhibition with trastuzumab with pertuzumab, an HER2 dimerization inhibitor antibody, demonstrated superior antitumor efficacy in HER2-positive breast cancer in both neoadjuvant and metastatic settings with improved overall survival over single HER2 blockade with trastuzumab. This evidence concerns the gene ERBB2 and breast carcinoma.